Adams Wealth Management Acquires Shares of 8,304 Hims & Hers Health, Inc. $HIMS

Key Points

• Adams Wealth Management has invested approximately $244,000 in Hims & Hers Health, Inc., purchasing 8,304 shares during the 1st quarter.
• Institutional investors currently hold 63.52% of Hims & Hers Health's stock, with significant purchases from firms like Farallon Capital Management and Yong Rong HK Asset Management.
• In its latest earnings report, Hims & Hers Health reported an EPS of $0.17, falling short of expectations, with revenue of $544.83 million representing a 72.6% increase from the previous year.

Adams Wealth Management bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 8,304 shares of the company's stock, valued at approximately $244,000.

A number of other institutional investors and hedge funds also recently modified their holdings of HIMS. Farallon Capital Management LLC lifted its holdings in Hims & Hers Health by 64,338.5% during the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after purchasing an additional 8,364,000 shares during the last quarter. Yong Rong HK Asset Management Ltd lifted its holdings in Hims & Hers Health by 41.2% during the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock valued at $70,920,000 after purchasing an additional 700,100 shares during the last quarter. Northern Trust Corp increased its position in Hims & Hers Health by 17.9% during the 4th quarter. Northern Trust Corp now owns 2,038,202 shares of the company's stock worth $49,284,000 after buying an additional 308,886 shares during the period. Nuveen LLC bought a new position in Hims & Hers Health during the 1st quarter worth $58,403,000. Finally, Two Sigma Investments LP increased its position in Hims & Hers Health by 37.9% during the 4th quarter. Two Sigma Investments LP now owns 1,967,354 shares of the company's stock worth $47,571,000 after buying an additional 540,274 shares during the period. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Price Performance

Shares of NYSE HIMS traded down $0.87 during trading hours on Monday, reaching $45.15. 21,505,342 shares of the stock traded hands, compared to its average volume of 37,348,528. The company has a market capitalization of $10.20 billion, a P/E ratio of 56.44, a price-to-earnings-growth ratio of 2.91 and a beta of 2.08. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. Hims & Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98. The company's 50-day simple moving average is $52.72 and its two-hundred day simple moving average is $45.77.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The company had revenue of $544.83 million during the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%. Hims & Hers Health's revenue for the quarter was up 72.6% on a year-over-year basis. During the same period last year, the firm earned $0.06 earnings per share. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on HIMS. Morgan Stanley reiterated an "equal weight" rating and set a $40.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Piper Sandler reissued a "neutral" rating and issued a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Truist Financial lowered their target price on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research report on Monday. UBS Group set a $30.00 price target on Hims & Hers Health in a report on Monday, June 23rd. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $38.92.

Insider Buying and Selling

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total value of $3,214,800.00. Following the transaction, the insider directly owned 169,940 shares of the company's stock, valued at $9,105,385.20. The trade was a 26.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 23,107 shares of Hims & Hers Health stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total value of $1,091,805.75. Following the completion of the transaction, the chief financial officer directly owned 63,222 shares in the company, valued at $2,987,239.50. This trade represents a 26.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,273,034 shares of company stock valued at $66,425,573 over the last quarter. Company insiders own 17.71% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.